Zai Lab reports strong Q3 2025 growth, advances pipeline

Zai Lab Limited reported unaudited product revenue of $115.4 million for Q3 2025, a 13% year-over-year increase, contributing to a total of $330.095 million for the nine months ended September 30, 2025. This growth was fueled by strong sales of NUZYRA and the recent launch of XACDURO, partially offset by softer ZEJULA sales. The company’s operating loss improved by 28% year-over-year to $48.8 million in Q3 2025, and adjusted its full-year 2025 revenue guidance to at least $460 million.

Key pipeline advancements include the initiation of a global registrational study for zocilurtatug pelitecan (zoci) in ES-SCLC and a global Phase 1 study for ZL-1503 in atopic dermatitis. KarXT was included in China's national treatment guidelines for schizophrenia, with an NDA accepted in January 2025. Regulatory milestones include Innovative Medical Device Designation for TTFields in pancreatic cancer and Breakthrough Therapy Designation for povetacicept in IgA nephropathy.

Organizational updates include the appointment of Dr. Shan He as senior vice president, chief business officer, and the formation of an Oncology Scientific Advisory Board. The company continues to invest in its global pipeline and expects to incur additional development and sales-based milestone payments in the future.